New drug trial aims to stop blood Cancer's comeback after transplant
NCT ID NCT06440135
Summary
This early-stage study is testing whether adding an experimental drug called ziftomenib to standard care after a bone marrow transplant is safe and can help keep acute myeloid leukemia (AML) from coming back. The study will enroll about 22 adults with specific genetic types of AML who are in remission and have just received a donor transplant. The main goal is to find the highest safe dose of ziftomenib that can be given for up to a year after the transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University Wexner Medical Center- James Cancer Hospital
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.